New deals extend Pyrosequencing AB's global market access
Uppsala, Sweden-based Pyrosequencing AB has entered into new distributoragreements for its PSQ 96 System, which it says is the first commercially-available, dedicated sequencing system for applied genetic analysis. The new agreements cover: eastern and central Europe through HVD; Spain and Portugal with IZASA SA; and Italy, which will be targeted by BioSense Srl.
The company says it will continue to maintain its own distribution in the major markets, and notes that the recent addition of a direct sales force in France completes that undertaking alongside the USA, UK, Scandinavia and Germany. For more information, visit the company's web site: www.pyrosequencing.com.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze